Iceland· IS-910073
Emla
A kombinationen von amid-lokalanästhetika product containing lidocainum inn,prilocainum inn, registered in Iceland by Aspen Pharma Trading Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Kombinationen von amid-lokalanästhetika is registered in 11 of 19 countries.
Countries holding a registration under ATC N01BB20 (kombinationen von amid-lokalanästhetika), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Kombinationen von amid-lokalanästhetika · ATC N01BB20
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lidocainum INN,Prilocainum INN
- Manufacturer
- Aspen Pharma Trading Limited
- Country
- Iceland (IS)
- ATC code
- N01BB20
- ATC class
- Kombinationen von Amid-Lokalanästhetika
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Kombinationen von amid-lokalanästhetika in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandAnesdermPierre Fabre Medicament
- United StatesCadira Compliant Blood StatAsclemed USA, Inc.
- United KingdomDenela 5% creamTeva UK Ltd
- SwitzerlandAnesderm
- FranceANESDERM 5 %, crèmePIERRE FABRE MEDICAMENT
- CzechiaEMLAAspen Pharma Trading Limited, Dublin
- FinlandEmlaAspen Pharma Trading Limited
- SwedenEMLA 25 mg/25 mg Medicinskt plåsterAspen Pharma Trading Limited
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Emla, Emla Pflaster
- Belgium · Emla, Emla Patch
- Cyprus · Emla, Xylocream
- Czechia · Emla
- Germany · Anesderm, Emla
- Denmark · Emla, Lidocain/Prilocain Idd
- Estonia · Nulbia
- Spain · Anamap®, Anestderma
- Finland · Emla, Oraqix
- France · Anesderm, Emla
- United Kingdom (Northern Ireland) · Emla, Nulbia
- Greece · Emla, Nulbia
- Hungary · Li-Pri
- Ireland · Emla, Oraqix
- Italy · Emla, Lidocaina E Prilocaina Teva
- Liechtenstein · Fortacin
- Luxembourg · Emla, Emla Patch
- Malta · Emla, Opralix
- Netherlands · Emla, Lidocaïne/Prilocaïne Teva
- Norway · Emla, Fortacin
- Poland · Anesderm, Emla
- Portugal · Emla, Emla Penso
- Romania · Romla
- Sweden · Emla, Oraqix
- Slovakia · Romla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b0493083-224e-4b58-b88c-af3eb5c6fd5f GET /v1/drugs/b0493083-224e-4b58-b88c-af3eb5c6fd5f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Lyfjaplástur",
"source": "lyfjastofnun",
"atc_raw": "N01BB20",
"marketed": true,
"strength": "25 mg/g + 25 mg/g",
"ma_number": "910073",
"substance": "Lidocainum INN,Prilocainum INN",
"other_info": "Lausasala 2 stk. pkn. og 20 stk. pkn.",
"legal_status": "(L) Ekki lyfseðilsskylt",
"ma_issued_serial": "34425"
}See everything about kombinationen von amid-lokalanästhetika.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.